文献速递前列腺癌

局限性前列腺癌患者在治疗风险与获益间的权衡:COMPARE研究

Evaluating the Trade-Offs Men with Localized Prostate Cancer Make between the Risks and Benefits of Treatments: The COMPARE Study.
PubMed 文献 · J Urol · 2020-01-22

COMPARE研究采用离散选择实验,在34个泌尿外科科室纳入低中危468例和高危166例局限性前列腺癌患者,在确诊后1周内、治疗决策前评估其对治疗特征的偏好。低中危患者愿以6.99%绝对生存下降换取主动监测而非根治性治疗;所有风险患者均愿以肿瘤特异性生存换取生活质量改善。

要点

  • 低中危患者愿以6.99%绝对生存下降换取主动监测。
  • 所有风险患者均愿以生存换取生活质量改善。
  • 高危患者愿以3.10%生存下降换取提前1个月恢复正常活动。

核心结论

  • 低中危局限性前列腺癌患者相比根治性治疗更偏好主动监测。
  • 所有风险水平的患者均愿意以肿瘤特异性生存换取生活质量改善。

研究设计与样本

  • 离散选择实验工具在34个泌尿外科科室开展,患者确诊后1周内、治疗决策前完成。
  • 低中危患者468例与高危患者166例使用不同工具,工具经5例预试验和106例 pilot 测试。
  • 采用误差成分条件logit模型估计偏好与权衡。

主要发现

  • 低中危患者愿以6.99%绝对生存下降换取主动监测而非根治性治疗。
  • 低中危患者愿以0.75%、0.46%和0.19%绝对生存下降分别换取恢复正常活动时间缩短1个月、泌尿功能和性功能绝对改善1%。
  • 高危患者愿以3.10%、1.04%和0.41%绝对生存下降分别换取恢复正常活动时间缩短1个月、泌尿功能和性功能绝对改善1%。

关键数值与推荐

  • 离散选择实验包含6个治疗特征:治疗类型(主动监测、局灶治疗、根治性治疗)、恢复正常活动、勃起功能、泌尿功能、无需更多癌症治疗、10至15年肿瘤特异性生存。

临床怎么用

  • 临床决策支持可参考患者对主动监测与根治性治疗的偏好及对生活质量的权衡。
  • 与患者沟通时应纳入恢复正常活动时间、泌尿功能和性功能等特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The COMPARE (COMparing treatment options for ProstAte cancer) study aimed to evaluate and quantify the trade-offs patients make between different aspects of active surveillance and definitive therapy. MATERIALS AND METHODS: A discrete choice experiment tool was used to elicit patient preferences for different treatment characteristics in 34 urology departments. Patients with localized prostate cancer completed the discrete choice experiment within 1 week of being diagnosed and before they made treatment decisions. The discrete choice experiment was pretested (5) and piloted (106) with patients. Patients chose their preferred treatment profile based on the 6 characteristics of treatment type (active surveillance, focal therapy, radical therapy), return to normal activities, erectile function, urinary function, not needing more cancer treatment and 10 to 15-year cancer specific survival. Different tools were designed for patients with low-intermediate (468) and high risk (166) disease. An error components conditional logit model was used to estimate preferences and trade-offs between treatment characteristics. RESULTS: Patients with low-intermediate risk disease were willing to trade 6.99% absolute decrease in survival to have active surveillance over definitive therapy. They were willing to trade 0.75%, 0.46% and 0.19% absolute decrease in survival for a 1-month reduction in time to return to normal activities and 1% absolute improvements in urinary and sexual function, respectively. Patients with high risk disease were willing to trade 3.10%, 1.04% and 0.41% absolute decrease in survival for a 1-month reduction in time to return to normal activities and 1% absolute improvements in urinary and sexual function, respectively. CONCLUSIONS: Patients with low-intermediate risk prostate cancer preferred active surveillance to definitive therapy. Patients of all risk levels were willing to trade cancer specific survival for improved quality of life.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Watson V, McCartan N, Krucien N, et al. Evaluating the Trade-Offs Men with Localized Prostate Cancer Make between the Risks and Benefits of Treatments: The COMPARE Study. J Urol. 2020. PMID: 31967521. doi:10.1097/JU.0000000000000754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。